

Title:

“Strategy for treating EGFR-TKI resistance in EGFR mutant lung cancer.”

Abstract:

The *BIM* deletion polymorphism, reported by Ong ST et al, is a novel resistant mechanism to EGFR-TKI in EGFR mutant lung cancer (LC). We found that the HDAC inhibitor, vorinostat, can epigenetically restore BIM function and death sensitivity to EGFR-TKI in EGFR mutant lung cancer with the *BIM* polymorphism. We have started a clinical trial with vorinostat and EGFR-TKI to circumvent *BIM* polymorphism-associated resistance. We will also elaborate on the mechanism and therapeutic strategy to overcome hepatocyte growth factor-triggered resistance.

Date:

**6 February 2015
(Friday)**

Time:

12:00 PM to 1:00 PM

Venue:

**Amphitheatre, Lvl 2
Duke-NUS Grad Med School
8 College Road, S169857**

(Opposite Singapore General Hospital, Block 6/7)

Host:

Sin Tiong ONG, MA, MRCP
Associate Professor
Program in Cancer & Stem Cell Biology
Duke-NUS Graduate medical School Singapore

“No registration is required.”

Any enquiry, please contact:
Lilian Poon (Tel: 6601 3779)

Speaker:



Dr. YANO Seiji, MD, PhD
Professor & Chairman
Division of Medical Oncology
Cancer Research Institute
Kanazawa University,
Japan

Biography:

Dr. YANO's research combines laboratory-based studies, with translational research and clinical trials of molecular targeted therapy in lung cancer patients. His main research interest is the understanding molecular mechanisms of resistance to targeted therapy, and developing novel therapeutics to treat the resistance in lung cancer. Dr Yano has received several awards for his research including 2013 JCA Mauvernay Award from Japanese Cancer Association.